“…First, however, it should be recognized that while the a motor activity role for NE is supported by a number of reports of behavioral hypoactivity after LC-noradrenergic lesions (Heybach et al, 1978; Owen et al, 1982; Ogren et al, 1983; Britton et al, 1984; Archer and Frediksson, 2003), there are an equal number showing little or no influence (Roberts et al, 1975; Porceddu et al, 1983; Sahakian et al, 1983; Britton et al, 1984; Archer et al, 1986; Sawynok et al, 1995; Neophytou et al, 2001; Srinivasan and Schmidt, 2004) and even some showing increases in baseline or stimulated activity in lesioned animals with high degrees of NE depletion (Ellison, 1975; Mason et al, 1978; 1979; Schwarting and Carey, 1988; Hatip-Al-Khatib and Bolukbasi, 1999; Murrough et al, 2000). These inconsistencies probably reflect inadequate experimental control of the complexities of the noradrenergic systems which possess the same receptors having opposite neural and behavioral functions depending on whether they are located at the LC or in terminal regions, and in which NE release can be affected either independently or concordantly with that of its peptide cotransmitter, galanin, by use of a selective NE-reuptake inhibitor or manipulation of nerve impulse rate, respectively (Stone et al, 2011b).…”